Objective: To detect recent infection in injection drug users (IDU) using the HIV-1 subtypes B, E, and D IgG-capture enzyme immunoassay (BED-CEIA) and estimate HIV-1 incidence in the IDU population in three cities of China.
Design: HIV-1-positive samples from IDU surveillance sentinel sites were collected for BED-CEIA, including 215 from city C (2001–2006), 433 from city D (2005), and 912 from city E (2000–2003). All 1560 samples were confirmed HIV positive with Western blot or alternative strategy.
Methods: HIV-1 incidence was calculated with BED-CEIA statistics software.
Results: City C: Annualized HIV-1 incidence among IDU of surveillance sentinel sites was 0.57–0.93% from 2000 to 2001, and approximately 1.0% from 2004 to 2006. City D: In IDU surveillance sentinel sites in 2005, the HIV-1 incidence was estimated to be 9.6%, whereas the incidence in all drug users was 2.1%. City E: IDU sentinel surveillance indicated a slight decrease in HIV-1 incidence from 9.2% in 2000 to 7.9% in 2003.
Conclusion: The HIV-1 incidence in IDU in city C was stable and relatively low. In contrast, there is a high HIV-1 incidence among IDU in cities D and E. The adjusted BED-CEIA estimated incidence rates indicate clearly that interventions must be strengthened continuously in IDU, especially in two Chinese cities.
From the aNational AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, Beijing, China
bHIV Confirmatory Central Laboratory, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China
cHIV Confirmatory Central Laboratory, Xinjiang Uigyur Autonomous Region Center for Disease Control and Prevention, Urumqi, Xinjiang, China
dHIV Confirmatory Laboratory, Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Dehong, Yunnan, China.
Correspondence to Yan Jiang, National AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, China CDC, Nanwei Road No 27, Beijing 100050, China. Tel: +86 10 63024898; fax: +86 10 63024898; e-mail: email@example.com